-
2 months ago | 
onlinelibrary.wiley.com | Milton Packer |Javed Butler |Baylor Scott
Invited Editorial The win ratio for trials for heart failure: academic desperation or investigator decadence? Milton Packer, Corresponding Author Milton Packer Baylor University Medical Center, Dallas, TX, USA Imperial College, London, UK Corresponding author. Baylor Heart and Vascular Institute, Baylor University Medical Center, 621 North Hall Street, Dallas, TX 75226, USA.
-
2 months ago | 
onlinelibrary.wiley.com | Stefan Anker |Tim Friede |Javed Butler |Baylor Scott
Introduction Iron deficiency (ID) is known to impair mitochondrial energy production and cause adverse cardiac remodelling leading to left ventricular dysfunction.1-4 ID is prevalent in up to 50% of patients with heart failure (HF) and is an independently associated with worse functional status, symptoms, and cardiovascular outcomes irrespective of anaemia.5, 6 The FAIR-HF (Ferinject Assessment in Patients with Iron Deficiency and Chronic Heart Failure) trial was the first major trial of...
-
Dec 10, 2024 | 
comparably.com | San Jose |Baylor Scott
The 8th annual list of Best Companies for Compensation recognizes organizations that were top-rated by employees for their total compensation packages over the past year (salary, raises, bonuses, benefits, and stock/equity if applicable). This distinction is segmented into two lists: Large companies (more than 500 employees) and Small/Mid-Size companies (500 or less employees).
-
Dec 9, 2024 | 
onlinelibrary.wiley.com | Muhammad Khan |Baylor Scott |Michael R. Zile
Introduction The global prevalence of atrial fibrillation (AF) is approximately 50 million, and it is estimated that in the US alone, 16 million people may have AF by 2050.1 As almost one third of the AF population is asymptomatic and has paroxysmal episodes, the worldwide AF burden is most likely under-estimated.2, 3 AF frequently co-exists with heart failure (HF) with each disease predisposing to the other.
-
Dec 8, 2024 | 
onlinelibrary.wiley.com | Anh Nguyen |Baylor Scott |Anjali Bhatt |Ambreen A. Merchant
Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.
-
Dec 6, 2024 | 
academic.oup.com | Joao Pedro |Université de Lorraine |João Sérgio |Baylor Scott
Many patients with heart failure (HF) and a preserved ejection fraction have anaemia as a consequence of ‘chronic disease’.
-
Nov 21, 2024 | 
newswise.com | Baylor Scott
Newswise — Baylor Scott & White Quality Alliance, the largest clinically integrated network in Texas, significantly exceeds average performance for nearly all quality measures tracked by the Medicare Shared Savings Program (MSSP). According to data released Oct. 29 by the Centers for Medicare & Medicaid Services (CMS), these efforts saved CMS $107.6 million in 2023.
-
Nov 21, 2024 | 
newswise.com | Baylor Scott
Newswise — A unique tactic to prevent post-traumatic stress disorder (PTSD) after a physical injury is being studied in patients at Level I trauma centers in three medical centers in Texas and Wisconsin: Baylor University Medical Center in Dallas Baylor Scott & White Medical Center – Temple Froedtert Hospital and the Medical College of Wisconsin The study, Prevention of Post-Traumatic Stress: A Randomized Controlled Trial of Brief Prolonged Exposure Therapy for Injured Individuals Admitted to...
-
Nov 12, 2024 | 
academic.oup.com | Enid Zuckerman College |Baylor Scott |Julie Mayo |Lauren E. W
While there is evidence that COVID-19 vaccination protects against development of post-COVID conditions (PCC) after severe infection data are limited on whether vaccination reduces the risk after cases of less-severe non-hospitalized COVID-19 disease with more recent SARS-CoV-2 variant viruses.
-
Nov 12, 2024 | 
karger.com | John Corbyn |Baylor Scott
Keywords:
Primary pulmonary artery sarcoma,
Dyspnea,
Pulmonary thromboembolism,
Cancer,
Intrathoracic sarcomas
Primary pulmonary artery sarcoma (PPAS) is a rare tumor with an estimated prevalence of 0.001–0.003% [1]. Pulmonary artery sarcomas are reported to have an average age of onset of 48 years old and can range from 13 to 86 years old [2]. Prognosis is poor with a median survival of 1.5 months without surgical intervention [3].
